Drug Trial Radar · NCT00790907
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
Last checked: Nov 20, 2026Latest source record: Mar 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,235
Actual
Start
Feb 2009
Primary completion
May 2010
Study completion May 2010
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 14, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST segment elevation myocardial infarction) who have been initially treated with fondaparinux.
Conditions
- Acute Coronary Syndrome
Interventions
fondaparinux background and standard dose UFHDrug
Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein \[GP\] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) \[maximum two additional bolus doses\]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
Fondaparinux background and low dose heparinDrug
Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
Open label fondaparinuxDrug
Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Composite of Major Bleeding, Minor Bleeding, or Major Vascular Access Site Complications During the Peri-PCI PeriodTime frame: Peri-PCI Period: occurred at randomization (from randomization to 48 hours after end of PCI procedure, typically 49 hours total)
Locations
203 sites in 18 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Ocala, Florida
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
Syracuse, New York
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
San Miguel de Tucumán, Argentina
GSK Investigational Site
Adrogué, Buenos Aires, Argentina
GSK Investigational Site
Bahía Blanca, Buenos Aires, Argentina
GSK Investigational Site
La Plata, Buenos Aires, Argentina
GSK Investigational Site
Merlo, Buenos Aires, Argentina
GSK Investigational Site
Quilmes, Buenos Aires, Argentina
GSK Investigational Site
Quilmes, Buenos Aires, Argentina
GSK Investigational Site
Rosario, Buenos Aires, Argentina
GSK Investigational Site
Corrientes, Corrientes Province, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
Santa Fe, Santa Fe Province, Argentina
GSK Investigational Site
Santa Fe, Santa Fe Province, Argentina
GSK Investigational Site
Campina Grande do Sul, Paraná, Brazil
GSK Investigational Site
Curitiba, Paraná, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Blumenau, Santa Catarina, Brazil
GSK Investigational Site
Campinas, São Paulo, Brazil
GSK Investigational Site
Marília, São Paulo, Brazil
GSK Investigational Site
São José do Rio Preto, São Paulo, Brazil
GSK Investigational Site
São José do Rio Preto, São Paulo, Brazil
GSK Investigational Site
Plovdiv, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Chicoutimi, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
Showing 40 of 203 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.